Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

4.95USD
13 Jan 2017
Change (% chg)

$0.20 (+4.21%)
Prev Close
$4.75
Open
$4.80
Day's High
$5.07
Day's Low
$4.80
Volume
74,367
Avg. Vol
109,182
52-wk High
$10.49
52-wk Low
$4.30

TGTX.OQ

Chart for TGTX.OQ

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $270.92
Shares Outstanding(Mil.): 54.73
Dividend: --
Yield (%): --

Financials

  TGTX.OQ Industry Sector
P/E (TTM): -- 46.47 30.92
EPS (TTM): -1.48 -- --
ROI: -81.79 -0.87 14.82
ROE: -83.43 -0.56 16.24

BRIEF-TG Therapeutics announces Orphan Drug Designation for the combination of TG-1101 and TGR-1202

* TG Therapeutics announces Orphan Drug Designation for the combination of TG-1101 and TGR-1202 for treatment of chronic lymphocytic leukemia Source text for Eikon: Further company coverage:

Jan 09 2017

BRIEF-TG Therapeutics announces positive DSMB recommendation

* TG Therapeutics announces positive DSMB recommendation for continuation of the UNITY-CLL phase 3 trial

Nov 22 2016

BRIEF-TG Therapeutics provides business update, reports Q3 results

* TG Therapeutics Inc provides business update and reports third quarter 2016 financial results

Nov 07 2016

BRIEF-Tg therapeutics launches early-stage study to treat phase patients with relapsed or refractory lymphoma

* Announces the launch of the phase 1/2 study of TGR-1202 and carfilzomib in patients with relapsed or refractory lymphoma

Oct 20 2016

BRIEF-TG Therapeutics amends phase 3 clinical trial

* TG Therapeutics Inc. Amends genuine phase 3 clinical trial to accelerate study completion by revising primary endpoint to overall response rate

Oct 13 2016

BRIEF-TG Therapeutics announces orphan drug designation for TG-1101

* TG Therapeutics announces orphan drug designation for TG-1101 for the treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder Source text for Eikon: Further company coverage:

Aug 26 2016

BRIEF-TG Therapeutics announces orphan drug designation for TGR-1202 for treatment of chronic lymphocytic leukemia

* TG Therapeutics announces orphan drug designation for TGR-1202 for treatment of chronic lymphocytic leukemia Source text for Eikon: Further company coverage:

Aug 24 2016

BRIEF-TG Therapeutics Q2 GAAP loss per share $0.33

* TG Therapeutics Inc announces second quarter 2016 financial results and business update

Aug 08 2016

Competitors

Earnings vs. Estimates